OIG Advisory Opinion: 22-22

    Favorable

    Free trial units of antipsychotic drug offered to hospitals

    Recorded opinion date:

    The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.

    What OIG Said

    OIG said this still counts as remuneration but allowed it due to tight controls and no link to referrals, billing, or continued use.

    ✓OIG reviewed a manufacturer’s plan to let hospitals request limited free doses of a long-acting antipsychotic for inpatient use. Doses were capped per hospital and per patient per year.

    ✓OIG confirmed these free trial units are “remuneration,” so the Anti-Kickback Statute applies, even though no one gets paid and the product isn’t billed.

    ✓The structure passed because: (a) prescribers had no financial incentive, (b) participation didn’t require ongoing use, (c) use had to be clinically appropriate and tracked, and (d) hospitals couldn’t bill for the drug or its administration.

    ✓OIG noted there was no obligation to continue prescribing the drug post-discharge, and the hospital couldn’t sell, trade, or seek reimbursement for free doses, helping reduce risk of disguised referral incentives.

    Diligence Checklist

    What you need to be ready to show in diligence

    ✓Show how any free or discounted drug/product is tracked, capped, and non-billable.

    ✓Prove prescriber decisions are independent, clinically appropriate, and not tied to product incentives.

    ✓Require certifications that prescribing is not conditional on continued use, payment, or referral volume.

    ✓Keep documentation that no patient, payer, or program was billed, and that the product wasn’t resold or distributed.

    ✓Ensure marketing and enrollment don’t resemble inducement or steerage, especially when multiple therapeutic alternatives exist.

    If you’re offering anything of value, even a sample, you need proof it’s clinically driven, not commercially motivated.

    Structure not diligence-ready?

    Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.

    Original PDF cover text

    FAVORABLE

    OIG WATCH 22-22

    Free trial units of antipsychotic drug offered to hospitals

    Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.

    Source documents

    Preparing document preview…

    Ready to Move Forward?

    Let's explore how we can support your goals